ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Interactive Brokers

Interactive Brokers
Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
Sign In Premium IconPremium Help Menu
S&P 500
4,967.23
-0.88%
US Tech 100
16,554.00
-2.26%
Dow Jones
37,986.40
0.56%
Brent Oil
86.625
0.00%
Bitcoin
63,923.21
0.15%
Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ

  6. Viridian Therapeutics Inc (VRDN) Quote

Viridian Therapeutics Inc

Viridian Therapeutics Inc (VRDN)

NASDAQ
14.60
-0.56
(-3.69%)
Closed April 20 4:00PM
Delayed by 15 minutes
14.60
0.00
(0.00%)
After Hours: 7:40PM
Delayed by 15 minutes

Unlock more advanced trading tools

Join ADVFN today

Key stats and details

Current Price
14.60
Bid
14.60
Ask
14.75
Volume
1,489,695
14.40 Day's Range 15.52
10.925 52 Week Range 30.30
Market Cap
916.407M
Previous Close
15.16
Open
15.09
Last Trade
5
@
14.78
Last Trade Time
Financial Volume
$ 22,645,813
VWAP
15.2016
Average Volume (3m)
898,814
Shares Outstanding
62,767,570
Dividend Yield
-
PE Ratio
-3.85
Earnings Per Share (EPS)
-3.79
Revenue
314k
Net Profit
-237.73M

About Viridian Therapeutics Inc

Viridian Therapeutics Inc is a clinical-stage biopharmaceutical company that engages in developing multiple product candidates to treat patients who suffer from thyroid eye disease. Its product candidate VRDN-001 is an insulin-like growth factor-1 receptor (IGF-1R) monoclonal antibody (mAb) being de... Viridian Therapeutics Inc is a clinical-stage biopharmaceutical company that engages in developing multiple product candidates to treat patients who suffer from thyroid eye disease. Its product candidate VRDN-001 is an insulin-like growth factor-1 receptor (IGF-1R) monoclonal antibody (mAb) being developed for the potential treatment for patients with thyroid eye disease. Show more

Sector
Medical Laboratories
Industry
Medical Laboratories
Website
www.viridiantherapeutics.com
Headquarters
Wilmington, Delaware, USA
Founded
1970
Viridian Therapeutics Inc is listed in the Medical Laboratories sector of the NASDAQ with ticker VRDN. The last closing price for Viridian Therapeutics was $15.16. Over the last year, Viridian Therapeutics shares have traded in a share price range of $ 10.925 to $ 30.30.

Viridian Therapeutics currently has 62,767,570 shares outstanding. The market capitalization of Viridian Therapeutics is $916.41 million. Viridian Therapeutics has a price to earnings ratio (PE ratio) of -3.85.

VRDN Latest News

More News

Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Viridian Therapeutics, Inc. (Nasdaq: VRDN) (the “company” or “Viridian”), a biopharmaceutical company focused on discovering and developing potential best-in-class medicines for serious and rare...

April 04 2024
Business Wire

Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Viridian Therapeutics, Inc. (Nasdaq: VRDN) (the “company” or “Viridian”), a biopharmaceutical company focused on discovering and developing potential best-in-class medicines for serious and rare...

March 06 2024
Business Wire

Viridian Therapeutics to Participate in the Leerink Partners Global Biopharma Conference

Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biopharmaceutical company focused on discovering and developing potential best-in-class medicines for serious and rare diseases, today announced that...

March 05 2024
Business Wire

Form S-8 - Securities to be offered to employees in employee benefit plans

February 28 2024
Edgar (US Regulatory)

Form 8-K - Current report

February 27 2024
Edgar (US Regulatory)

Viridian Therapeutics Highlights Recent Progress and Reports Fourth Quarter and Full Year 2023 Financial Results

- VRDN-001 Phase 3 THRIVE and THRIVE-2 topline clinical data readouts are expected for mid-year 2024 and year-end 2024, respectively - - Subcutaneous VRDN-003 pivotal program in thyroid eye...

February 27 2024
Business Wire

Viridian Therapeutics Appoints Jennifer Tousignant as Chief Legal Officer

Viridian Therapeutics, Inc. (Nasdaq: VRDN) (the “company” or “Viridian”), a biopharmaceutical company focused on discovering and developing potential best-in-class medicines for serious and rare...

February 16 2024
Business Wire

Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]

February 14 2024
Edgar (US Regulatory)

Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]

February 14 2024
Edgar (US Regulatory)

Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]

February 14 2024
Edgar (US Regulatory)
PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
1-1.67-10.264290104516.2716.3214.471543115.40804771CS
4-4.09-21.883360085618.6918.9414.473296516.54874503CS
12-5.46-27.218344965120.0621.4614.489881418.05388433CS
262.7222.895622895611.8824.1810.92592846617.97419718CS
52-14.04-49.022346368728.6430.310.92581261319.32842802CS
1560.322.2408963585414.28399.4749980020.69736666CS
260-6.79-31.743805516621.39399.4746434520.68007116CS

Market Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
TWGTop Wealth Group Holding Ltd
$ 3.73
(101.62%)
36.52M
CSLRComplete Solaria Inc
$ 0.465319
(75.59%)
16.64M
SHOTWSafety Shot Inc
$ 0.48
(60.00%)
6.71k
EGOXNext e GO NV
$ 0.0515
(43.06%)
333.3M
MNDRMobile health Network Solutions
$ 27.2386
(33.72%)
10.35M
YYAIConnexa Sports Technologies Inc
$ 0.8943
(-57.21%)
13.4M
SBFMSunshine Biopharma Inc
$ 1.77
(-46.69%)
11.9M
GTIGraphjet Technology
$ 6.43
(-33.09%)
95.33k
ISPCiSpecimen Inc
$ 0.2883
(-31.52%)
2.86M
BGLCBioNexus Gene Lab Corporation
$ 0.5998
(-29.32%)
735.88k
EGOXNext e GO NV
$ 0.0515
(43.06%)
333.3M
SQQQProShares UltraPro Short QQQ
$ 12.84
(6.38%)
219.91M
AGBAAGBA Group Holding Ltd
$ 1.255
(21.84%)
128.79M
TQQQProShares UltraPro QQQ
$ 49.48
(-6.20%)
125.4M
SINTSiNtx Technologies Inc
$ 0.0414
(3.50%)
109.94M

VRDN Discussion

View Posts
Apprentice Apprentice 3 years ago
I put into it a lot of $
423 shares!
👍️0
Apprentice Apprentice 3 years ago
It just doesn't want to move above $18
Yet, it's not diving much either.
What do you think at this point? Sell temporarily and by later low?
My average is too high @17.76 !
👍️0
crudeoil24 crudeoil24 3 years ago
Viridian Therapeutics, Inc., formerly Miragen Therapeutics, Inc., is a biotechnology company. The Company is engaged in developing multiple product candidates to treat patients who suffer from thyroid eye disease (TED), a debilitating orphan disease, and has early-stage programs focused on other targets and indications. Its lead candidate, VRDN-001, is a clinical-stage anti-IGF-1R monoclonal antibody (mAb) that is under development for thyroid eye disease (TED). The Company's TED pipeline also includes VRDN-002 and VRDN-003. Its other programs include VRDN-004, which is under development for undisclosed rare orphan disease, and VRDN-005, which is under development for tick-borne disease (TBD). The Company also out licenses its programs.
👍️0

Your Recent History

NASDAQ
VRDN
Viridian Therapeutics
Delayed Upgrade Clock
ADVFN Logo

United States
Company
Business
Popular
Get The App

Support: 1-888-992-3836 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2024 ADVFN PLC - All Rights Reserved